Abstract: Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.

Abstract: The invention provides compounds of the formula: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a, Z and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.

Abstract: Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.

Abstract: A transparent load balancer receives incoming Ethernet frames having incoming source and destination IP and MAC addresses. The load balancer diverts the incoming frames to one of several multi-application platforms. The incoming frames are communicated across a first TCP connection that terminates on a multi-application platform. The first TCP connection is defined by TCP source and destination ports. The transparent load balancer receives outgoing frames from the multi-application platform and outputs the outgoing frames with source and destination IP and MAC addresses that are identical to the incoming source and destination IP and MAC addresses. The outgoing frames are communicated across a second TCP connection, the second TCP connection being defined by the same TCP source port and TCP destination port of the first TCP connection. The transparent load balancer and multi-application platforms can be inserted into a running network without noticeable interruption to devices on the network.

Abstract: A portable LED lamp can be removably attached to a stand. The stand has connectors that are usable to retain the lamp as well as supply power to the lamp from an external-power supply source. The connectors can also serve as pivot points for a user to pivot the portable LED lamp when it is attached to the stand. In some embodiments, a dual level circuit board assembly is also provided for the portable LED lamp, with LEDs coupled to both levels of the circuit board assembly.

Abstract: A multi-application transparent platform intercepts an incoming application file communicated from a source across a first TCP connection by terminating the first TCP connection on the multi-application transparent platform and supplying the application file to an application program. The application file is received onto the platform in the form of multiple incoming Ethernet frames. The application layer program analyzes the application file and identifies characteristics of the application file, such as virus content, that are not apparent in the individual Ethernet frames that carried the application file over the first TCP connection. The platform resends the application file over a second TCP connection in outgoing frames having the same IP addresses and Ethernet MAC addresses as the incoming frames. The platform can be inserted into a running network without reconfiguring devices on the network.

Abstract: A timer usable in navigating and piloting an aircraft, the timer having a plurality of application modes for management of time and numeric data, including an approach mode, a fuel mode, a chronograph mode and a clock mode. Each application mode can drive independent but simultaneous time count sequences for use in flight management and navigation such as counting down approach times, fuel-tank switching intervals and other time sensitive events, as well as providing military time, standard time and UTC time.

Abstract: In accordance with the teachings described herein, systems and methods are provided for providing environmental specific noise reduction algorithms (ESNRAs) in a head-mounted device. A network server may be used to store a plurality of ESNRAs. One or more of the ESNRAs may be downloaded from the network server for use in the head-mounted device. The head-mounted device may use one or more of the downloaded ESNRAs to filter environmental noise from an audio signal.

Abstract: The present invention encompasses compounds of Formula (I) and Formula (II) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions.

Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.

Abstract: A timer usable in navigating and piloting an aircraft, the timer having a plurality of application modes for management of time and numeric data, including an approach mode, a fuel mode, a chronograph mode and a clock mode. Each application mode can drive independent but simultaneous time count sequences for use in flight management and navigation such as counting down approach times, fuel-tank switching intervals and other time sensitive events, as well as providing military time, standard time and UTC time.

Abstract: A jadeite material has a thickness in excess of about 1.0 mm and CIELAB indices of L*>42, a*<?6, and b*>+6. The grain size of the jadeite material is less than about 30 microns and is an equiaxed grain structure. The jadeite material has an optical transmission peak between 500 and 565 nm with an I/IO optical transmission ratio of over 40%. The first step in making the jadeite material is to wrap a glass block, convertible by HP/HT into jadeite and having a nominal composition of NaAlSi2O6, with a graphite or refractive metal sheet. The wrapped glass block is placed in an HP/HT apparatus, rapidly heated, and subjected therein to a pressure in excess of about 3 GPa and a temperature in excess of about 1000° C. for a time adequate to convert the glass block into jadeite. The jadeite material then is cooled and the pressure subsequently released.

Abstract: The present invention provides compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein R1 and R2 are independently hydrogen, an option ally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and R3 is an optionally substituted C3-20 heterocyclyl or C5-20 aryl group, and their use as pharmaceuticals, particularly in treating diseases which are retroviral mediated or ameliorated by the inhibition of DNA-PK,